Investigating the binding mechanism of sphingosine kinase 1/2 inhibitors: Insights into subtype selectivity by homology modeling, molecular dynamics simulation and free energy calculation studies

被引:12
作者
Zhang, Jinmiao [1 ]
Zhang, Maoyu [1 ]
Yu, Jinying [2 ]
Shang, Yanguo [2 ]
Jiang, Kaixuan [2 ]
Jia, Yihe [2 ]
Wang, Jinxin [2 ]
Yang, Kan [1 ]
机构
[1] Hebei Univ, Coll Pharmaceut Sci, Key Lab Pharmaceut Qual Control Hebei Prov, Baoding 071002, Peoples R China
[2] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China
关键词
Sphingosine kinase; Inhibitors; Molecular dynamics simulation; Selectivity; FUNCTIONAL-CHARACTERIZATION; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; DISCOVERY; CLONING; CANCER; DERIVATIVES; RESPONSES; DOCKING; DESIGN;
D O I
10.1016/j.molstruc.2020.127900
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Sphingosine 1-phosphate (S1P) is a lipid signaling molecule that is implicated in a variety of pathologies, including cancer, inflammation and pulmonary arterial hypertension. Sphingosine kinases (SPHK1 and SPHK2) are the key targets in the synthesis of S1P. However, selective and potent inhibitors of SPHK are lacking, especially for SPHK2. In this work, we predicted the detailed interactions between the inhibitors and SPHK using various molecular modeling methods. As a result, some residues (Asp 81, Ile174, Asp178, Phe288 of SPHK1 and Leu297, Ser298, Asp308 of SPHK2) were found as key binding sites of their inhibitors. The reason why PF543 is highly SPHK1 selective might be that its sulfonyl group conflicts with residue His556 of SPHK2. In SPHK1, the corresponding residue is His397. Compounds with a substituent occupying the pocket made up by His397 may show high selectivity towards SPHK1. Moreover, in case of SPHK2, introducing suitable substituents that insert into the region of Cys533 or designing a flexible polar head that interacts with Leu297 and Ser298 might improve the selectivity towards SPHK2. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页数:8
相关论文
共 44 条
[1]   Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2 [J].
Adams, David R. ;
Tawati, Salha ;
Berretta, Giacomo ;
Rivas, Paula Lopez ;
Baiget, Jessica ;
Jiang, Zhong ;
Alsfouk, Aisha ;
Mackay, Simon P. ;
Pyne, Nigel J. ;
Pyne, Susan .
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (07) :3658-3676
[2]   Sphingosine Kinases: Emerging Structure-Function Insights [J].
Adams, David R. ;
Pyne, Susan ;
Pyne, Nigel J. .
TRENDS IN BIOCHEMICAL SCIENCES, 2016, 41 (05) :395-409
[3]   Molecular dynamics simulation of zika virus NS5 RNA dependent RNA polymerase with selected novel non-nucleoside inhibitors [J].
Ahmad, Nasir ;
Rehman, Ashfaq Ur ;
Badshah, Syed Lal ;
Ullah, Asad ;
Mohammad, Akhtar ;
Khan, Khalid .
JOURNAL OF MOLECULAR STRUCTURE, 2020, 1203
[4]   Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2 [J].
Alvarez, Sergio E. ;
Harikumar, Kuzhuvelil B. ;
Hait, Nitai C. ;
Allegood, Jeremy ;
Strub, Graham M. ;
Kim, Eugene Y. ;
Maceyka, Michael ;
Jiang, Hualiang ;
Luo, Cheng ;
Kordula, Tomasz ;
Milstien, Sheldon ;
Spiegel, Sarah .
NATURE, 2010, 465 (7301) :1084-U149
[5]   Antiestrogenic Effects of the Novel Sphingosine Kinase-2 Inhibitor ABC294640 [J].
Antoon, James W. ;
White, Martin D. ;
Meacham, William D. ;
Slaughter, Evelyn M. ;
Muir, Shannon E. ;
Elliott, Steven ;
Rhodes, Lyndsay V. ;
Ashe, Hasina B. ;
Wiese, Thomas E. ;
Smith, Charles D. ;
Burow, Matthew E. ;
Beckman, Barbara S. .
ENDOCRINOLOGY, 2010, 151 (11) :5124-5135
[6]   Synthesis, homology modeling, molecular docking, dynamics, and antifungal screening of new 4-hydroxycoumarin derivatives as potential chitinase inhibitors [J].
Batran, Rasha Z. ;
Khedr, Mohammed A. ;
Latif, Nehad A. Abdel ;
Abd El Aty, Abeer A. ;
Shehata, Abeer N. .
JOURNAL OF MOLECULAR STRUCTURE, 2019, 1180 :260-271
[7]   An update on the biology of sphingosine 1-phosphate receptors [J].
Blaho, Victoria A. ;
Hla, Timothy .
JOURNAL OF LIPID RESEARCH, 2014, 55 (08) :1596-1608
[8]   The Sphingosine Kinase 1/Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension [J].
Chen, Jiwang ;
Tang, Haiyang ;
Sysol, Justin R. ;
Moreno-Vinasco, Liliana ;
Shioura, Krystyna M. ;
Chen, Tianji ;
Gorshkova, Irina ;
Wang, Lichun ;
Huang, Long Shuang ;
Usatyuk, Peter V. ;
Sammani, Saad ;
Zhou, Guofei ;
Raj, J. Usha ;
Garcia, Joe G. N. ;
Berdyshev, Evgeny ;
Yuan, Jason X. -J. ;
Natarajan, Viswanathan ;
Machado, Roberto F. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 190 (09) :1032-1043
[9]   Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity [J].
Childress, Elizabeth S. ;
Kharel, Yugesh ;
Brown, Anne M. ;
Bevan, David R. ;
Lynch, Kevin R. ;
Santos, Webster L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (09) :3933-3957
[10]   A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors [J].
Dickson, Mark A. ;
Carvajal, Richard D. ;
Merrill, Alfred H., Jr. ;
Gonen, Mithat ;
Cane, Lauren M. ;
Schwartz, Gary K. .
CLINICAL CANCER RESEARCH, 2011, 17 (08) :2484-2492